We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Radiotherapy with cetuximab could also be superior to radiotherapy alone for sufferers who endure surgical procedure for head, neck most cancers
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Radiotherapy with cetuximab could also be superior to radiotherapy alone for sufferers who endure surgical procedure for head, neck most cancers
Radiotherapy with cetuximab could also be superior to radiotherapy alone for sufferers who endure surgical procedure for head, neck most cancers
Health

Radiotherapy with cetuximab could also be superior to radiotherapy alone for sufferers who endure surgical procedure for head, neck most cancers

Last updated: January 27, 2025 8:00 pm
Editorial Board Published January 27, 2025
Share
SHARE

Credit score: Unsplash/CC0 Public Area

Outcomes from the Part III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or with out concurrent cetuximab for chosen sufferers with squamous cell most cancers of the top and neck (SCCHN) confirmed that radiotherapy with cetuximab demonstrated superiority as measured by improved disease-free survival, a secondary endpoint.

The research additionally confirmed no enhance in long-term toxicity. The trial outcomes, nevertheless, didn’t present a statistically important enchancment in total survival, the first endpoint. These outcomes have been revealed within the Journal of Medical Oncology.

“Currently, the outcomes for patients with HPV-negative SCCHN remain poor and treatment is associated with a high rate of locoregional failure and death, despite surgical resection with postoperative radiotherapy,” acknowledged Mitchell Machtay, MD, of the Pennsylvania State College Most cancers Institute and the lead creator of the NRG-RTOG 0920 manuscript.

“Given that EGFR is a common hallmark of SCCHN, our hope was that adding cetuximab to postoperative radiotherapy could help improve outcomes for these patients without the burden of additional long-term toxicity.”

NRG-RTOG 0920 enrolled 577 eligible sufferers with SCCHN of the oral cavity, oropharynx, or larynx, and with a number of intermediate-risk components that warranted postoperative radiotherapy, however not excessive dose cisplatin chemotherapy. Most tumors (85%) had excessive EGFR expression.

Sufferers have been randomly assigned to obtain both IMRT (60–66 Gy) with weekly cetuximab (C+RT) or radiotherapy alone (RT). The first goal of this trial was to find out if the addition of cetuximab to radiotherapy improved total survival. Illness-free survival and toxicity have been secondary endpoints.

Total survival at a median follow-up of seven.2 years was not considerably improved (hazard ratio [HR] 0.81; one-sided p=0.075; five-year estimates 76.5% for C+RT and. 68.7% for RT alone) however disease-free survival was (HR 0.75; one-sided p=0.017; five-year estimates 71.7% for C+RT and 63.6% for RT alone).

The profit found with the addition of cetuximab was solely seen within the HPV-negative subpopulation (80% of the sufferers within the trial). Grade 3–4 acute toxicity charges have been 39.7% (RT) and 70.3% (C+RT) (two-sided p

“These data would indicate that adding cetuximab to radiotherapy is an appropriate option for carefully selected patients with HPV-negative disease,” Dr. Machtay added, “particularly those for whom cisplatin-based chemotherapy with radiation is not a good choice.”

Extra info:
Mitchell Machtay et al, Postoperative Radiotherapy ± Cetuximab for Intermediate-Threat Head and Neck Most cancers, Journal of Medical Oncology (2025). DOI: 10.1200/JCO-24-01829

Offered by
NRG Oncology

Quotation:
Radiotherapy with cetuximab could also be superior to radiotherapy alone for sufferers who endure surgical procedure for head, neck most cancers (2025, January 27)
retrieved 27 January 2025
from https://medicalxpress.com/information/2025-01-radiotherapy-cetuximab-superior-patients-surgery.html

This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

Microscopy reveals how Hippo pathway proteins management gene exercise in most cancers

Mind peptide ODN reduces starvation and boosts glucose regulation in rat research

‘Weekend warrior’ exercises cut back diabetics’ threat of demise, examine signifies

New technique estimates measles vaccination charges with out up-to-date survey knowledge

First of its type research explores symptom prevalence throughout the menopause transition

TAGGED:CancercetuximabNeckpatientsradiotherapysuperiorsurgeryundergo
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
At the moment in Historical past: December 7, Japan assaults Pearl Harbor
World

At the moment in Historical past: December 7, Japan assaults Pearl Harbor

Editorial Board December 7, 2024
WR Garrett Wilson noncommittal about remaining with Jets long-term
Luke Weaver can’t bail Devin Williams out as Yankees lose late to Padres
Live Updates: At Least 50 Killed in Strike on Train Station, Ukraine Says, as Thousands Flee From East
How Thomson Reuters and Anthropic constructed an AI that tax professionals truly belief

You Might Also Like

Plant virus triggers immune response that targets and destroys most cancers cells
Health

Plant virus triggers immune response that targets and destroys most cancers cells

July 26, 2025
Variety of household caregivers has skyrocketed within the US
Health

Variety of household caregivers has skyrocketed within the US

July 26, 2025
First-of-its form examine reveals psychological toll of warfare in Gaza extends far past the area
Health

First-of-its form examine reveals psychological toll of warfare in Gaza extends far past the area

July 26, 2025
Scientists develop tissue-healing gel utilizing milk-derived extracellular vesicles
Health

Scientists develop tissue-healing gel utilizing milk-derived extracellular vesicles

July 26, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?